Oriflame today announced significant new findings from its research on Oripeptide-3, the brand’s patented bio activating technology and core ingredient of the NovAge+ range. The technology has been shown to support five key biological drivers of skin ageing, reinforcing Oriflame’s two-decade commitment to cellular health, skin longevity, and science-driven skincare solutions.
Developed to work in harmony with the skin’s natural biology, Oripeptide-3 targets DNA protection, protein quality, cellular renewal, energy for repair, and overall skin function. “Longevity is the next frontier in beauty, and Oripeptide-3 demonstrates our leadership in advanced research at the molecular and cellular level,” said Dr. Lene Visdal-Johnsen, Director, Scientific Research and Innovation, Oriflame Global R&D. Edyta Kurek, Senior Vice President & Head, Oriflame India and Indonesia, added that the innovation addresses growing consumer demand for long-term, evidence-based skincare benefits.
In Shillong, the launch of the Nov Age+ range has sparked increased consumer interest, with local Oriflame partner outlets reporting rising demand among urban professionals seeking premium, science-backed anti-ageing solutions. Analysts note that the city represents a key growth market in northeast India for advanced skincare products.
Operating in over 60 countries, Oriflame continues to strengthen its corporate vision of combining innovation, sustainability, and wellbeing to deliver long-term skin health solutions globally.
1
+ There are no comments
Add yours